Document Detail


Thrombosis, thrombophilia, and thromboprophylaxis in pregnancy.
MedLine Citation:
PMID:  16166990     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Normal pregnancy is accompanied by changes in coagulation that have likely evolved to protect women from the bleeding challenges of miscarriage and childbirth. Consequently, pregnant women are at an increased risk of thrombosis. The most important risk factors are thrombophilia and a history of thrombosis. Most thromboses in pregnancy occur in the left lower extremity, but pelvic vein thromboses are not uncommon. Thrombophilia increases not only the risk of maternal thrombosis but also the risk of poor pregnancy outcome. All pregnant women should be asked about a personal or family history of thrombosis and the details of their obstetrical history. Some women should undergo laboratory testing, particularly those with a personal history of thrombosis or a history of poor pregnancy outcome. The purpose of testing is to help determine which women should receive anticoagulation therapy, which is used not only to treat venous thromboembolism, but also to prevent thromboembolism and reduce the risk of poor pregnancy outcome in women with thrombophilia. Low-molecular-weight heparins are preferred over unfractionated heparin because they have a longer half-life and are presumed to have fewer side effects. Their longer half-life is a disadvantage around the time of delivery when unfractionated heparin, with its shorter half-life, is easier to manage. The risk of thrombosis is higher postpartum than during pregnancy, so anticoagulation therapy is usually continued for at least 6 weeks after delivery.
Authors:
Andra H James; Leo R Brancazio; Thomas L Ortel
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Clinical advances in hematology & oncology : H&O     Volume:  3     ISSN:  1543-0790     ISO Abbreviation:  Clin Adv Hematol Oncol     Publication Date:  2005 Mar 
Date Detail:
Created Date:  2005-09-16     Completed Date:  2007-09-21     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101167661     Medline TA:  Clin Adv Hematol Oncol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  187-97     Citation Subset:  IM    
Affiliation:
Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC 27710, USA. andra.james@duke.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Algorithms
Anticoagulants / adverse effects,  pharmacokinetics,  therapeutic use*
Autoimmune Diseases / chemically induced,  immunology
Blood Coagulation Tests
Disease Susceptibility
Female
Fetal Diseases / etiology
Heparin / adverse effects,  pharmacokinetics,  therapeutic use
Heparin, Low-Molecular-Weight / adverse effects,  pharmacokinetics,  therapeutic use
Humans
Postnatal Care
Pregnancy
Pregnancy Complications, Hematologic / epidemiology,  etiology,  prevention & control*
Pregnancy Outcome
Prenatal Care
Puerperal Disorders / prevention & control
Retrospective Studies
Risk Factors
Thrombocytopenia / chemically induced,  immunology
Thromboembolism / epidemiology,  etiology,  prevention & control
Thrombophilia / diagnosis,  drug therapy*,  etiology,  genetics
Thrombophlebitis / etiology,  prevention & control
Thrombosis / epidemiology,  prevention & control*
Chemical
Reg. No./Substance:
0/Anticoagulants; 0/Heparin, Low-Molecular-Weight; 9005-49-6/Heparin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Gastric cancer.
Next Document:  The development of molecularly targeted anticancer therapies: an Eli Lilly and Company perspective.